Pubblicazioni

Neoadjuvant Therapy for Rectal Cancer: Updates From the UNICANCER-PRODIGE 23 Trial

2022 - CLINICAL COLORECTAL CANCER

Neoadjuvant therapy for rectal cancer: updates from the UNICANCER-PRODIGE 23 trial

2022 - CLINICAL COLORECTAL CANCER
De Felice, Francesca; Musio, Daniela; Tombolini, Vincenzo; Cortesi, Enrico

Adjuvant chemotherapy in resected colon cancer: when, how and how long?

2019 - SURGICAL ONCOLOGY
Gelibter, A. J.; Caponnetto, S.; Urbano, F.; Emiliani, A.; Scagnoli, S.; Sirgiovanni, G.; Napoli, V. M.; Cortesi, E.

Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer. A single-institution experience

2015 - CANCER CHEMOTHERAPY AND PHARMACOLOGY
Petrioli, R; Francini, E; Roviello, F; Marrelli, D; Fiaschi, Ai; Laera, L; Rossi, G; Bianco, V; Brozzetti, Stefania; Roviello, G.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma